OTCMKTS:CYBN Cybin (CYBN) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free cybn Stock Alerts $0.35 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.3550-Day Range$0.32▼$0.4652-Week Range$0.21▼$0.74Volume2.16 million shsAverage Volume5.05 million shsMarket Capitalization$143.80 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings Get Cybin alerts: Email Address Cybin MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,042.9% Upside$7.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.19) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCybin has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CYBN. Previous Next 0.0 Dividend Strength Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYBN. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 19 people have searched for CYBN on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows21 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.94% of the stock of Cybin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($0.19) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Cybin Stock (OTCMKTS:CYBN)Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.Read More CYBN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYBN Stock News HeadlinesApril 19, 2024 | americanbankingnews.comCybin (OTCMKTS:CYBN) Stock Price Down 2%April 18, 2024 | businesswire.comCybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 16, 2024 | businesswire.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 19, 2024 | businesswire.comCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 18, 2024 | businesswire.comCybin to Present at Public Ventures Discovery Day on March 19th in DallasMarch 15, 2024 | businesswire.comCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderMarch 14, 2024 | markets.businessinsider.comCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy RatingMarch 14, 2024 | msn.comCybin to begin Phase 3 study for psychedelic drug mid-yearMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA DesignationsMarch 14, 2024 | businesswire.comCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program DesignMarch 13, 2024 | markets.businessinsider.comCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003March 13, 2024 | businesswire.comCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive DisorderMarch 12, 2024 | businesswire.comCybin to Host Conference Call and Webcast to Provide Program Update for CYB003March 10, 2024 | investorplace.com3 High-Potential Penny Stocks to Turn $1000 into $1 millionFebruary 27, 2024 | businesswire.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 16, 2024 | thestreet.comCybin Inc.February 14, 2024 | finance.yahoo.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | businesswire.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 7, 2024 | finance.yahoo.comCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT ProgramJanuary 23, 2024 | msn.comFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized AnxietyJanuary 23, 2024 | msn.comCybin gets FDA clearance for Phase 2a study of psychedelic drugJanuary 23, 2024 | finance.yahoo.comCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety DisorderSee More Headlines Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:CYBN CUSIPN/A CIK1833141 Webwww.cybin.com Phone(866) 292-4601FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,042.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.17% Return on Assets-84.68% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual Sales$680,000.00 Price / Sales211.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.84Miscellaneous Outstanding Shares410,855,000Free Float170,213,000Market Cap$143.80 million OptionableNot Optionable Beta0.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Eric So L.L.B. (Age 48)Co-Founder, President & Executive Chairman Comp: $455.15kMr. Douglas L. Drysdale (Age 54)Chief Executive Officer Comp: $608.45kMr. Paul Glavine (Age 35)Co-Founder, Chief Growth Officer & Director Comp: $455.15kMr. Greg Cavers (Age 53)Chief Financial Officer Comp: $240.12kMr. Aaron BartloneChief Operating OfficerMr. John Kanakis (Age 44)Co-Founder Comp: $698.3kDr. Alex L. Nivorozhkin Ph.D. (Age 64)Chief Scientific Officer Ms. Lori ChallengerChief Compliance, Ethics & Administrative OfficerMr. Gabriel Fahel (Age 48)Chief Legal Officer & Corporate Secretary Sara Brittany SomersetChief Communications OfficersMore ExecutivesKey CompetitorsNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEBiopharmxNYSEAMERICAN:BPMXNervGen PharmaOTCMKTS:NGENFAmpliphi BiosciencesNYSEAMERICAN:APHBView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 13,960,000 shares on 4/25/2024Ownership: 3.398%Thrive Wealth Management LLCSold 45,300 shares on 4/16/2024Ownership: 0.020%View All Institutional Transactions CYBN Stock Analysis - Frequently Asked Questions Should I buy or sell Cybin stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYBN shares. View CYBN analyst ratings or view top-rated stocks. What is Cybin's stock price target for 2024? 2 brokers have issued 12 month target prices for Cybin's shares. Their CYBN share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 2,042.9% from the stock's current price. View analysts price targets for CYBN or view top-rated stocks among Wall Street analysts. How have CYBN shares performed in 2024? Cybin's stock was trading at $0.41 at the beginning of 2024. Since then, CYBN stock has decreased by 14.6% and is now trading at $0.35. View the best growth stocks for 2024 here. How were Cybin's earnings last quarter? Cybin Inc. (OTCMKTS:CYBN) released its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.04. Who are Cybin's major shareholders? Cybin's stock is owned by many different retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (3.40%) and Thrive Wealth Management LLC (0.02%). How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYBN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
